Your session is about to expire
← Back to Search
Allosteric Activator
Long-Term Mitapivat for Sickle Cell Disease
Phase 1 & 2
Waitlist Available
Led By Julia Z Xu, M.D.
Research Sponsored by National Heart, Lung, and Blood Institute (NHLBI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
1.6 For women of reproductive potential, have a negative serum pregnancy test during the screening period. Women of reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy, or tubal occlusion; or who have not been naturally postmenopausal (i.e., who have not menstruated at all for at least the preceding 1 year prior to signing informed consent unrelated to hormonal contraception).
f. Activated partial thromboplastin time and international normalized ratio <=1.5 x ULN, unless the subject is receiving therapeutic anticoagulants.
Must not have
a. Poorly controlled hypertension (defined as systolic blood pressure [BP] >150 mmHg or diastolic BP >90 mmHg) refractory to medical management.
g. Iron overload sufficiently severe to result in a clinical diagnosis by the Investigator of cardiac (e.g., clinically significant impaired left ventricular ejection fraction), hepatic (e.g., fibrosis, cirrhosis), or pancreatic (e.g., diabetes) dysfunction.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 and 48 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing the long-term tolerability and safety of mitapivat (or AG-348) in people with sickle cell disease.
Who is the study for?
Adults aged 18-70 with Sickle Cell Disease (SCD) who previously participated in NIH study #19H0097 and benefited from it. They must have stable organ function, no recent blood transfusions, and for women of childbearing potential, a commitment to use two forms of contraception. Exclusions include significant heart rhythm issues, uncontrolled medical conditions like hypertension or diabetes, active infections or certain drug allergies.
What is being tested?
The trial is testing the long-term safety and effectiveness of mitapivat tablets taken twice daily by people with SCD. It extends a previous study to see if benefits continue or improve over time. Participants will undergo various health assessments including physical exams, blood tests, heart checks (ECG), mobility tests (6-minute walk), echocardiograms for heart/lung function, bone scans (DXA), and health questionnaires.
What are the potential side effects?
While specific side effects are not listed here, participants will monitor any symptoms they experience in a study diary which may include typical drug-related reactions such as digestive discomforts, potential liver enzyme changes due to medication metabolism challenges or other common medication-induced complications.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a woman who can have children and have a negative pregnancy test.
Select...
My blood clotting tests are within normal limits, unless I'm on blood thinners.
Select...
My kidney function, measured by creatinine levels or filtration rate, is within the normal range.
Select...
I am between 18 and 70 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My high blood pressure is not controlled by medication.
Select...
I have been diagnosed with heart, liver, or pancreas problems due to high iron levels.
Select...
I haven't had a severe infection or needed strong antibiotics in the last 8 weeks.
Select...
I have had a bone marrow or stem cell transplant.
Select...
I have stopped taking strong CYP3A4/5 inhibitors or inducers for the required time before giving consent.
Select...
I have not used blood cell-boosting drugs in the last 90 days.
Select...
I have a blood disorder other than mild issues from blood transfusions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 and 48 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 and 48 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
measure: Long-term safety and tolerability of mitapivat in subjects with stable sickle cell disease
Secondary study objectives
To evaluate hemoglobin (Hb) response, changes in hemolytic markers, functional status, cardiopulmonary function, and health-related quality of life in SCD subjects maintained on mitapivat long-term.
To evaluate the pharmacokinetic
To monitor SCD-related safety endpoints in SCD subjects maintained on mitapivat long-term.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
Subjects will be treated with a maintenance dose of mitapivat previously assessed for safety and tolerability in the Phase I study for an initial 48 weeks and undergo safety monitoring, evaluation of pharmacokinetics and pharmacodynamics, and assessment of secondary laboratory and clinical endpoints at pre-specified intervals during the study period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mitapivat
2023
Completed Phase 1
~20
Find a Location
Who is running the clinical trial?
National Heart, Lung, and Blood Institute (NHLBI)Lead Sponsor
3,938 Previous Clinical Trials
47,792,283 Total Patients Enrolled
Julia Z Xu, M.D.Principal InvestigatorNational Heart, Lung, and Blood Institute (NHLBI)
Swee Lay Thein, M.D.Principal InvestigatorNational Heart, Lung, and Blood Institute (NHLBI)
12 Previous Clinical Trials
7,910 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had gallstones or gallbladder inflammation but it's treated now.I am a woman who can have children and have a negative pregnancy test.My high blood pressure is not controlled by medication.My blood clotting tests are within normal limits, unless I'm on blood thinners.My organs are functioning well.My diabetes is not well-controlled, or I need more than 3 medications, including insulin.I have been diagnosed with heart, liver, or pancreas problems due to high iron levels.I haven't had a severe infection or needed strong antibiotics in the last 8 weeks.I am willing to undergo screening for a study and understand I might not qualify.I have had a bone marrow or stem cell transplant.My diagnosis of HbSS was confirmed by tests at least 3 months after my last blood transfusion.My kidney function, measured by creatinine levels or filtration rate, is within the normal range.I am between 18 and 70 years old.I have had cancer before, but it was either skin, cervical, or breast cancer treated with the intent to cure, and I've been free of active disease and treatment for 3 years.I have stopped taking strong CYP3A4/5 inhibitors or inducers for the required time before giving consent.I have tested positive for hepatitis B or C with active infection signs.I have not used blood cell-boosting drugs in the last 90 days.I completed Study 19H0097 and meet all its criteria except for 1.4, 2.2, and 2.3.p.I have a blood disorder other than mild issues from blood transfusions.I am not in another clinical trial and haven't taken voxelotor or crizanlizumab recently.My heart rhythm problems are considered significant by my doctor.You have had an allergic reaction in the past to mitapivat or any of its ingredients.I haven't had serious heart issues or blood clots in the last 6 months.
Research Study Groups:
This trial has the following groups:- Group 1: 1
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.